GYRE THERAPEUTICS INC (GYRE) Institutional Ownership Changes & 13F Activity
GYRE THERAPEUTICS INC (GYRE). Institutional ownership data tracks hedge funds, asset managers, and other institutional investors based on recent SEC Form 13F filings (Q2 2026). This page analyzes institutional buying and selling activity, new holdings, and sold-out positions in the latest reporting period. Notable filers include Hsg Holding Ltd, Octagon Capital Advisors Lp, Vanguard Capital Management Llc, Geode Capital Management, Llc, and Vanguard Portfolio Management Llc.
| Institution | Type | Change in shares | Change Position % | Shares | Reported stock balance | Portfolio quarter | Filing date |
|---|---|---|---|---|---|---|---|
| California State Teachers Retirement System | Sell | -473 | -74.0% | 166 | $1.09K | Q2 2026 | Aug 24, 2026 |
| Octagon Capital Advisors Lp | Buy | +954,416 | — | 954,416 | $6.29M | Q2 2026 | Aug 14, 2026 |
| Charles Schwab Investment Management Inc | Buy | +19,048 | +11.5% | 184,286 | $1.21M | Q2 2026 | Aug 14, 2026 |
| Millennium Management Llc | Buy | +18,488 | — | 18,488 | $121.84K | Q2 2026 | Aug 14, 2026 |
| Price T Rowe Associates Inc | Buy | +15,031 | — | 15,031 | $100.00K | Q2 2026 | Aug 14, 2026 |
| Goldman Sachs Group Inc | Buy | +13,113 | +17.9% | 86,235 | $568.29K | Q2 2026 | Aug 14, 2026 |
| Wells Fargo & Company/Mn | Buy | +12,007 | +279.9% | 16,297 | $107.40K | Q2 2026 | Aug 14, 2026 |
| Polymer Capital Management (Us) Llc | Buy | +11,780 | — | 11,780 | $77.63K | Q2 2026 | Aug 14, 2026 |
| Royal Bank Of Canada | Buy | +7,590 | +135.4% | 13,195 | $87.00K | Q2 2026 | Aug 14, 2026 |
| Mirae Asset Global Etfs Holdings Ltd. | Buy | +2,829 | +50.4% | 8,446 | $55.66K | Q2 2026 | Aug 14, 2026 |
| Alliancebernstein L.P. | Buy | +2,760 | +12.6% | 24,590 | $171.39K | Q2 2026 | Aug 14, 2026 |
| Bank Of America Corp | Buy | +1,987 | +18.9% | 12,525 | $82.54K | Q2 2026 | Aug 14, 2026 |
| Barclays Plc | Buy | +928 | +40.3% | 3,228 | $21.27K | Q2 2026 | Aug 14, 2026 |
| Legal & General Group Plc | Buy | +803 | +64.2% | 2,054 | $13.54K | Q2 2026 | Aug 14, 2026 |
| Osaic Holdings, Inc. | Buy | +6 | +15.8% | 44 | $288.00 | Q2 2026 | Aug 14, 2026 |
| Hsg Holding Ltd | Buy | +3,750,299 | — | 3,750,299 | $24.71M | Q2 2026 | Aug 13, 2026 |
| Vanguard Capital Management Llc | Sell | -107,277 | -10.9% | 876,927 | $5.78M | Q2 2026 | Aug 13, 2026 |
| Vanguard Portfolio Management Llc | Buy | +54,139 | +77.5% | 123,953 | $816.85K | Q2 2026 | Aug 13, 2026 |
| Northern Trust Corp | Buy | +35,696 | +26.7% | 169,537 | $1.12M | Q2 2026 | Aug 13, 2026 |
| Morgan Stanley | Buy | +33,050 | +382.5% | 41,691 | $274.74K | Q2 2026 | Aug 13, 2026 |
| Vanguard Fiduciary Trust Co | Buy | +13,391 | +9.7% | 151,073 | $995.57K | Q2 2026 | Aug 13, 2026 |
| Fmr Llc | Sell | -3,743 | -20.0% | 14,974 | $98.68K | Q2 2026 | Aug 13, 2026 |
| Ubs Group Ag | Sell | -2,324 | -11.0% | 18,763 | $123.65K | Q2 2026 | Aug 13, 2026 |
| Bnp Paribas Financial Markets | Buy | +915 | +35.6% | 3,486 | $22.97K | Q2 2026 | Aug 13, 2026 |
| Geode Capital Management, Llc | Buy | +101,536 | +23.5% | 532,950 | $3.51M | Q2 2026 | Aug 12, 2026 |
| Jpmorgan Chase & Co | Buy | +7,831 | — | 7,831 | $50.51K | Q2 2026 | Aug 12, 2026 |
| Rhumbline Advisers | Buy | +3,749 | +28.6% | 16,865 | $111.13K | Q2 2026 | Aug 12, 2026 |
| Optiver Holding B.V. | Sell | -96 | -94.1% | 6 | $40.00 | Q2 2026 | Aug 12, 2026 |
| Nuveen, Llc | Buy | +24,505 | — | 24,505 | $161.49K | Q2 2026 | Aug 11, 2026 |
| Tower Research Capital Llc (Trc) | Sell | -3,294 | -57.2% | 2,469 | $16.27K | Q2 2026 | Aug 11, 2026 |
Frequently asked questions about GYRE activity
Which institutional owners are buying GYRE?
Institutional owners buying GYRE include investors who have either initiated new positions or increased their existing holdings based on recent SEC 13F filings. The activity table above highlights which funds added shares in the latest reporting periods and how their positions changed over time.
What does "buy" mean in GYRE activity?
"Buy" means an investor increased their reported position in GYRE compared to the prior reporting period. This reflects growing exposure to GYRE THERAPEUTICS INC (GYRE) rather than necessarily a brand-new position (though new positions also appear as buys when prior quantity was zero).
Is institutional interest in GYRE increasing?
Institutional interest in GYRE can be assessed by comparing the number of tracked funds adding or increasing positions versus those trimming or exiting across the periods shown. A higher number of additions typically signals increasing participation among large filers, but it should be read alongside position sizes and the full table.
Related GYRE Institutional Insights
- GYRE Overview
- GYRE 13F Institutional Holders
- GYRE Top Institutional Shareholders
- Healthcare Sector Institutional Ownership
- Healthcare Sector Portfolio Overlap
- Institutional Portfolio Overlap & Shared Holdings
- Most Bought Healthcare Stocks By Institutional Investors
- Most Sold Healthcare Stocks By Institutional Investors
- GYRE Insider Trading & SEC Form 4 Activity
- GYRE Articles
- Top Institutional Investor Stock Rankings